title: Use of structure based design to increase selectivity of pyridyl-cinnoline phosphodiesterase 10A (PDE10A) inhibitors against phosphodiesterase 3 (PDE3).
abstract: We report our successful effort to increase the PDE3 selectivity of PDE10A inhibitor pyridyl cinnoline 1 using a combination of computational modeling and structural-activity relationship investigations. An analysis of the PDE3 catalytic domain compared to the co-crystal structure of cinnoline analog 1 in PDE10A revealed two areas of structural differences in the active sites and suggested areas on the scaffold that could be modified to exploit those unique structural features. Once SAR established the cinnoline as the optimal scaffold, modifications on the methoxy groups of the cinnoline and the methyl group on the pyridine led to the discovery of compounds 33 and 36. Both compounds achieved significant improvement in selectivity against PDE3 while maintaining their PDE10A inhibitory activity and in vivo metabolic stability comparable to 1.
authors.affiliation: Department of Small Molecule Chemistry, Amgen Inc., One Amgen Center Drive, Thousand Oaks, CA 91320-1799, USA. ehu@amgen.com
authors.forename: Essa
authors.initials: E
authors.lastname: Hu
authors.forename: Roxanne K
authors.initials: RK
authors.lastname: Kunz
authors.forename: Shannon
authors.initials: S
authors.lastname: Rumfelt
authors.forename: Kristin L
authors.initials: KL
authors.lastname: Andrews
authors.forename: Chun
authors.initials: C
authors.lastname: Li
authors.forename: Stephen A
authors.initials: SA
authors.lastname: Hitchcock
authors.forename: Michelle
authors.initials: M
authors.lastname: Lindstrom
authors.forename: James
authors.initials: J
authors.lastname: Treanor
mesh_terms: D000818:Animals; D001665:Binding Sites; D020134:Catalytic Domain; D018360:Crystallography, X-Ray; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3 / Q000737:chemistry* / Q000378:metabolism; D015195:Drug Design; D006207:Half-Life; D006574:Heterocyclic Compounds, 2-Ring / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D010726:Phosphodiesterase Inhibitors / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D010727:Phosphoric Diester Hydrolases / Q000737:chemistry* / Q000378:metabolism; D011725:Pyridines / Q000138:chemical synthesis / Q000737:chemistry* / Q000493:pharmacokinetics; D051381:Rats; D013329:Structure-Activity Relationship
chemical_list: D006574:Heterocyclic Compounds, 2-Ring; D010726:Phosphodiesterase Inhibitors; D011725:Pyridines; C119843:PDE10A protein, human; D010727:Phosphoric Diester Hydrolases; D054684:Cyclic Nucleotide Phosphodiesterases, Type 3; C476282:cinnoline